TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV schizophrenic or schizoaffective patients between 18 and 55 years old with a PANSS score above 45.~Exclusion Criteria:~* Clinical disease~* Pregnancy~* Drug dependence (except for nicotine) in the past month and history of being refractory to at least 2 antipsychotics taken appropriately.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. born male, or born female and does not identify as female;~2. reports anal sex with men in the prior three months while under the influence of meth;~3. diagnosed with meth dependence by SCID;~4. interested in stopping or reducing meth use;~5. at least one meth-positive urine during screening and run-in period;~6. no current acute illness requiring prolonged medical care;~7. no serious chronic illnesses that are likely to progress clinically during trial participation;~8. able and willing to provide informed consent and adhere to visit schedule;~9. age 18-69 years;~10. baseline CBC, total protein, albumin, glucose, alkaline phosphatase, creatinine, BUN, and electrolytes without clinically significant abnormalities as determined by clinician in conjunction with symptoms, physical exam, and medical history~11. current CD4 count ≥ 200 cells/mm3; or CD4 count of 100 - 199 cells/mm3 and HIV viral load \< 200 copies/mL~12. text-capable cell phone or access to email~Exclusion Criteria:~1. Evidence of current major depression by SCID;~2. history of bipolar disorder or psychotic disorder, as determined by SCID;~3. known allergy or previous adverse reaction to mirtazapine;~4. taking an anti-depressant medication within the past 30 days, including mirtazapine or a monoamineoxidase inhibitor;~5. moderate or severe liver disease (AST, ALT, and total bilirubin \>= 5 times upper limit of normal);~6. impaired renal function (estimated GFR \<40 ml/min);~7. currently participating in another research study;~8. pending legal proceedings with high risk for incarceration during the time of planned study participation;~9. any condition that, in the principal investigator's judgment, interferes with safe study participation or adherence to study procedures.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Mirtazapine (Type: ACTIVE_COMPARATOR): mirtazapine 30 mg orally per day
- Placebo (Type: PLACEBO_COMPARATOR): placebo (30 mg) orally per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant was prescribed aripiprazole, olanzapine, quetiapine, or risperidone.~* Participant possessed a smartphone, or a smartphone provided by the Sponsor, and was willing to download and interact with the DMS app.~* Skin on the anterior chest just above the lower edge of the rib cage was free of any dermatological problems (for example, open wounds, warts, rashes, atopic dermatitis).~Exclusion Criteria:~* Participant with a known allergy to adhesive tape or any pertinent components of the patch or CoE product.~* Prisoners could not be enrolled into this trial.~* Participant who was hospitalized due to mental or physical illness (inpatient) at the time of screening/baseline.~* Any participant who, through religious or lifestyle choices, would not take gelatin capsules.~* Female of childbearing potential who was breast-feeding and/or who had a positive pregnancy test result prior to receiving trial enrollment, or who planned to become pregnancy during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole (Type: EXPERIMENTAL): Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
- Olanzapine (Type: EXPERIMENTAL): Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
- Quetiapine (Type: EXPERIMENTAL): Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
- Risperidone (Type: EXPERIMENTAL): Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Haploidentical-Cord Blood Transplantation for Adults and Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients will be eligible for this study if they have any one of the diseases that are known to be cured after allogeneic stem cell transplantation.~1. Relapsed or refractory acute leukemia (myeloid or lymphoid)~2. Acute leukemia in first remission at high-risk for recurrence~3. Chronic myelogenous leukemia in accelerated phase or blast-crisis~4. Chronic myelogenous leukemia in chronic phase~5. Recurrent or refractory malignant lymphoma or Hodgkin lymphoma~6. Chronic lymphocytic leukemia, relapsed or with poor prognostic features~7. Multiple myeloma~8. Myelodysplastic syndrome~9. Chronic myeloproliferative disease~10. Hemoglobinopathies~11. Aplastic anemia~Exclusion Criteria:~1. Zubrod performance status \> 2~2. Life expectancy is severely limited by concomitant illness~3. Patients with severely decreased LVEF or impaired pulmonary function tests(PFT's)~4. Estimated Creatinine Clearance \<50 ml/min~5. Serum bilirubin\> 2.0 mg/dl or SGPT \>3 x upper limit of normal~6. Evidence of chronic active hepatitis or cirrhosis~7. HIV-positive~8. Patient is pregnant~9. Patient or guardian not able to sign informed consent

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Good Risks patients (Type: EXPERIMENTAL): For patients transplanted in remission.
- High Risk Patients eligible for radiation (Type: EXPERIMENTAL): None
- High Risk Patients not eligible for radiation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas~* Metastatic disease~* Documented disease progression after treatment with 1 line of prior gemcitabine-based regimen~* Karnofsky performance status equal or more than 70~Exclusion Criteria:~* With active CNS metastases~* With clinically significant gastrointestinal disorder (e.g., bleeding, inflammation, occlusion, or diarrhea \> grade 1)~* Major surgery or radiotherapy within 4 weeks~* Prior participation in any investigational drug study within 4 weeks~* With prior irinotecan treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEP02 (Type: EXPERIMENTAL): Liposome Irinotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Severe alcohol withdrawal defined by a CIWA score ≥ 15 and the need for at least 16 mg of lorazepam over a four-hour period. All lorazepam doses, whether oral or intravenous, will contribute to the cumulative amount.~2. Patients receiving standard therapy for severe alcohol withdrawal according to a symptom-triggered alcohol withdrawal protocol. Lorazepam is the preferred benzodiazepine agent for patients requiring ICU admission due to alcohol withdrawal.~3. Informed consent within 36 hours of qualifying for the study.~Exclusion Criteria:~1. Patients \< 18 years of age or \> 85 years of age.~2. Patients receiving benzodiazepine therapy for purposes other than alcohol withdrawal (e.g. sedation).~3. Patients with alcohol withdrawal not requiring ICU admission.~4. Patients receiving epidural administration of medication(s).~5. Comatose patients by metabolic or neurologic affectation.~6. Patients with active myocardial ischemia or second- or third-degree heart block.~7. Moribund state with planned withdrawal of life support.~8. Patients with known or suspected severe adverse reactions to dexmedetomidine (or clonidine).~9. Pregnant females or females suspected of being pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine, low dose (Type: EXPERIMENTAL): Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
- Dexmedetomidine, high dose (Type: EXPERIMENTAL): Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Self-Management of Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Radiographic evidence of hip or knee osteoarthritis~* Current / persistent joint symptoms (pain, aching, stiffness)~Exclusion Criteria:~* Other rheumatic disease (i.e., rheumatoid arthritis, fibromyalgia)~* Hospitalization for stroke or cardiovascular event within past 3 months~* Metastatic cancer~* Active diagnosis of psychosis~* Terminal illness~* On waiting list for arthroplasty~* Resident of nursing home~* Severely impaired in hearing or speech (participants must be able to respond to phone calls)~* Significant cognitive dysfunction~* No access to a telephone~* Current participation in another interventional study for osteoarthritis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Health Education Intervention (Type: ACTIVE_COMPARATOR): Health Education Intervention
- Usual Medical Care (Type: NO_INTERVENTION): Usual Medical Care
- Osteoarthritis Self-Management (Type: EXPERIMENTAL): Osteoarthritis Self-Management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged 5-17 years, with appropriately obtained informed consent and assent.~2. Subject has a documented history of ulcerative colitis for at least 3 months.~3. Subjects who are currently on 5-ASA or product(s) containing or metabolized to mesalamine must have been on a stable regimen for at least 4 weeks prior to first dose of investigational medicinal product.~4. Subjects who are not currently on a drug regimen, or on a 5-ASA or product containing or metabolized to mesalamine, must have been on a stable regimen for at least 4 weeks prior to first dose at least 4 weeks prior first dose of investigational medicinal product.~5. Body weight of 18kg-82kg inclusive.~Exclusion Criteria:~1. Current or recurrent disease (eg cardiovascular, renal, liver, malignancy or other conditions) that could affect the colon, the action, absorption or disposition of the IMP, or clinical or laboratory assessments with the exception of their existing ulcerative colitis.~2. Ulcerative Colitis known to be confined to the rectum (isolated rectal proctitis).~3. Any history of hepatic impairment or moderate to severe renal impairment.~4. The use of systemic or rectal steroids within the last 4 weeks, immunomodulators within the last 6 weeks, biologics within 6 months, antibiotic use within the last 7 days prior to the first dose of investigational medicinal product.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- MMX Mesalamine (30mg/kg) (Type: EXPERIMENTAL): None
- MMX Mesalamine (60 mg/kg) (Type: EXPERIMENTAL): None
- MMX Mesalamine (100 mg/kg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Participants who (or whose parent/legal representative) are able to give written informed consent.~* Participants must be 10 years of age or older and 17 years of age or younger at the time of treatment assignment (randomization).~* Participants must have a diagnosis of bipolar I disorder, confirmed by structured interview at screening.~* Participants must not be pregnant or lactating, and those who are sexually active or become sexually active during the trial, and of child-bearing potential, must be using a medically accepted form of birth control.~* Participants will be required to have stopped taking certain psycho-active medications prior to baseline.~* Participants must have a caregiver, or other responsible person living with them who agrees to provide support to the participant to ensure study and procedure compliance.~Exclusion criteria:~* Diagnosis of bipolar II disorder, or other form of bipolar or psychotic disorder.~* Known or suspected mental retardation.~* Substance abuse, or dependence, within the past 6 months.~* There is risk of self-harm or harm to others.~* There is a history of tardive dyskinesia or dystonia.~* Pregnancy or lactation during the study.~* History of seizure disorder.~* Participation in any other clinical trial at the same time.~* A family member who is part of the study staff or is directly involved with the study.~* Other medical conditions determined by the study staff to possibly interfere with the study safety and efficacy evaluations.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Asenapine 2.5 mg twice daily (BID) (Type: EXPERIMENTAL): Participants receive asenapine 2.5 mg BID for 21 days.
- Asenapine 5.0 mg BID (Type: EXPERIMENTAL): Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive asenapine 5.0 mg BID for the remainder of the 21-day treatment period.
- Asenapine 10.0 mg BID (Type: EXPERIMENTAL): Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. On Day 5 and 6 participants receive asenapine 5.0 mg BID. On Day 7 participants receive asenapine 5.0 mg in the morning and 10.0 mg in the evening. Participants receive asenapine 10.0 mg BID for the remainder of the 21-day treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo BID for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-capillary Pulmonary Hypertension patients assessed by right heart catheterization~* Signed informed consent~Exclusion Criteria:~* Patient belonging to post-capillary, Isolated post-capillary, or combined post -capillary and pre-capillary pulmonary hypertension according to 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.~* Moderate to severe chronic pulmonary obstructive disease~* Right Ventricular Ejection Fraction \> 45% assessed by cardiac magnetic resonance.~* Documented left ventricular dysfunction with left ventricular ejection fraction \< 50% assessed by cardiac magnetic resonance.~* Severe renal impairment (Serum creatinine \> 2.5 mg/dL, eGFR \< 30ml/min/1.73 m\^2, or routine dialysis treatment).~* Malignant arrhythmia such as total atrioventricular block or ventricular fibrillation or unstable ventricular tachycardia.~* Patients who are receiving or have been receiving any investigational drugs within 1 month before the baseline visit~* Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements~* Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements~* Females who are lactating or pregnant or those who plan to become pregnant during the study~* Known Parkinson disease~* Known hypersensitivity to any of the drug formulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sugar pill (Type: PLACEBO_COMPARATOR): The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
- trimetazidine (Type: EXPERIMENTAL): The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insomnia Self-Management in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* stable chronic heart failure, chronic insomnia, English speaking/reading,~Exclusion Criteria:~* untreated sleep disordered breathing or restless legs syndrome, rotating/night shift work, active illicit drug use, bipolar disorder, neuromuscular conditions affecting the non-dominant arm end-stage renal failure, significant cognitive impairment, unstable medical or psychiatric disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Therapy (Type: EXPERIMENTAL): Cognitive behavioral therapy for insomnia (CBT-I) will be provided in a group format, led by an interventionist. CBT-I includes strategies for modifying thoughts and behaviors about sleep. Participants will be instructed on and practice methods for modifying their thoughts and behaviors about sleep and insomnia. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
- Heart Failure Self-Management Education (Type: ACTIVE_COMPARATOR): Heart Failure Self-management education is an intervention that will be provided by a nurse in a group format. This includes standard components, such as education about fluid and sodium management, heart failure medications, diet and physical activity. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete